Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.62 |
| ▸ | RARG | P13631 | 11/20 | 0.62 |
| ▸ | RXRA | P19793 | 4/20 | 0.62 |
| ▸ | RARA | P10276 | 13/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9190385 | 0.85 | RARA (0.50) | RARBRARGRXRARARAPDK2 | |
| SCHEMBL8557384 | 0.85 | RARB (0.55) | RARBRARGRXRARARAPDK2 | |
| SCHEMBL7877006 | 0.84 | RARB (0.64) | RARBRARGRXRARARAPDK2 | |
| SCHEMBL7794229 | 0.82 | RARB (0.75) | RARBRARGRXRARARARXRB | |
| SCHEMBL7569488 | 0.81 | PDK2 (0.45) | RARBRARGRXRARARAPDK2 | |
| SCHEMBL7565236 | 0.81 | CD274 (0.51) | RARBRARGRXRARARAPDK2 | |
| SCHEMBL7564650 | 0.81 | PDK2 (0.45) | RARBRARGRXRARARAPDK2 | |
| SCHEMBL8347608 | 0.80 | RARB (0.65) | RARBRARGRXRARARARXRB | |
| SCHEMBL7793710 | 0.80 | RARB (0.62) | RARBRARGRXRARARAABCB1 | |
| SCHEMBL24794240 | 0.76 | RARG (0.58) | RARBRARGRXRARARAPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0848696-B1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6313163-B1 | ADMINISTERING 2,4-PENTADIENOIC ACID DERIVATIVE FOR THERAPY OF DISEASE OR CONDITION RESPONSIVE TO THERAPY BY RETINOIDS | ALLERGEN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6114533-A | A COMPOUNDS HAVING A 2,4-PENTADIENOIC ACID OR 2,4-PENTADIENOIC ACID ESTER FUNCTION WHICH IS SUBSTITUTED IN THE 5-POSITION WITH TETRAHYDROQUINOLINYL GROUP | ALLERGAN SALES, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6034242-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-5917082-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999008992-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5817836-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN (US) | 1998-10-06 | — | — | US | disclosed |
| US-5801253-A | Retinoic acid X-receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5780647-A | 2,4-Pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0848696-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5675033-A | FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663367-A | REGULATOR OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0775103-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996039374-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996005165-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | RXRA, RXRB, CBR1 | RARB 13/4885RARG 30/4885RXRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.